For full FDA category definitions, please click here. The following information is intended for use by competent health care professionals and academia. You assume full responsibility for ensuring the appropriate use and reliance upon this information. The prescribed dose should be administered orally, once daily with a meal and a large glass of water. Treatment should be continued as long as the patient continues to benefit.
Elimination is predominately in the feces, mostly as metabolites.
When the 10 mg daily dose is tolerated, the maintenance dose of 30 mg may be initiated. In most patients, escalation to 30 mg can be accomplished in 3 to 7 days. The overall half-life of alemtuzumab is approximately 12 days. Infusion-related events including fever, chills, rigors, nausea, bronchospasm, and rash are common adverse effects of alemtuzumab. Alemtuzumab causes profound lymphopenia.